Dark

Check out our Level2View

APLIF
APPILI THERAPEUTICS INC
stock OTC

EOD

May 12, 2025

0.0208USD-16.466%(-0.0041)10,000

Pre-market

Dec 31, 1969

0.00USD-100.000%(-0.02)0

After-hours

Dec 31, 1969

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Dec 28, 2021

09:03AM EST Aditxt Signs Share Exchange Agreement to Acquire AiPharma in Cash, Stock Deal Benzinga

Nov 30, 2021

04:09PM EST APLIF: PRESECO Trial Unsuccessful in COVID-19 Benzinga

Nov 19, 2021

07:42AM EST Appili Therapeutics Announces Positive One Year Challenge Results from Preclinical Study Evaluating Biodefense Vaccine Candidate ATI-1701 and Change to Board of Directors Business Wire

Nov 12, 2021

05:41PM EST Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2022 and Change of Chief Financial Officer Business Wire

07:19AM EST Appili Therapeutics Provides Update on Phase 3 PRESECO Clinical Trial Evaluating Avigan(r)/Reeqonus(tm) Business Wire

Sep 29, 2021

09:59AM EDT AiPharma Enters Into Alliance And Stock Swap Agreement With Appili Therapeutics RTTNews

09:57AM EDT AiPharma Enters into Strategic Alliance and Stock Swap Agreement with Appili PR Newswire

07:39AM EDT Appili Therapeutics and AiPharma Announce Strategic Alliance and Equity Transaction Business Wire

Sep 23, 2021

07:51AM EDT Appili Therapeutics Announces Last Patient Enrolled In Phase 3 Trial Of Oral Avigan/Reeqonus For COVID-19 RTTNews

07:48AM EDT Appili Therapeutics Announces Last Patient Enrolled in Phase 3 Trial of Oral Avigan(r)/Reeqonus(tm) for the Treatment of Mild-to-Moderate COVID-19 Business Wire

Sep 20, 2021

07:51AM EDT Appili Announces Deal With FUJIFILM&Funding Support For Trial Program Evaluating Avigan/Reeqonus For COVID-19 Patients RTTNews

07:44AM EDT Appili Therapeutics Announces Agreement with FUJIFILM and Funding Support for Clinical Trial Program Evaluating Avigan(r)/Reeqonus(tm) for COVID-19 Patients Business Wire

Sep 17, 2021

07:17AM EDT Appili Therapeutics Announces Completion of Patient Enrollment for Avigan(r)/Reeqonus(tm) Viral Shedding Sub- Study for Mild-to-Moderate COVID-19 Patients Business Wire

Sep 8, 2021

07:17AM EDT Appili Therapeutics Announces Results for Resolutions at Annual General Meeting of Shareholders Business Wire

Sep 6, 2021

09:41AM EDT APLIF: Awaiting Data Readout for Phase 3 PRESECO Trial in Benzinga

Aug 13, 2021

07:32AM EDT Appili Therapeutics Q1 Loss $7.4 Mln Or $0.12/shr Vs. Loss $2.6 Mln Or $0.05/shr Prior Year RTTNews

07:17AM EDT Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2022 Business Wire

Jun 28, 2021

12:31PM EDT APLIF: DSMB Recommends for PRESECO Trial to Complete; Data Expected in 3Q21 Benzinga

Jun 24, 2021

07:17AM EDT Appili Therapeutics Reports Fiscal Year 2021 Financial and Operational Results and Provides Update on Strategy for Fiscal 2022 Business Wire

May 17, 2021

09:43AM EDT DSMB Recommends Appili Complete Phase 3 Avigan/Reeqonus Trial For Mild-to-Moderate COVID-19 Patients RTTNews

08:31AM EDT Complete Its Phase 3 Avigan(r)/Reeqonus(tm) Trial for Mild-to-Moderate COVID-19 Patients PR Newswire

Apr 19, 2021

07:17AM EDT Appili Therapeutics to Present at the Bloom Burton & Co. Healthcare Investor Virtual Conference on Wednesday, April 21st, 2021 Business Wire

Mar 17, 2021

07:17AM EDT Appili Therapeutics to Participate in M Vest LLC and Maxim Group LLC Inaugural Emerging Growth Virtual Conference on Friday, March 19th Business Wire

Feb 24, 2021

07:17AM EST Appili Therapeutics to Present as Part of Canada's Top Three Pitches at Biocom's Global Life Science Partnering Conference Today Business Wire

Dec 22, 2020

01:22AM EST Dr. Reddy's, Global Response Aid, Appili Therapeutics Announce Filing Of Application For REEQONUS Tablets RTTNews

01:18AM EST Dr. Reddy's, Appili Therapeutics File Application For REEQONUS Tablets For COVID-19 Under Health Canada's Interim Order RTTNews

01:11AM EST Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics Announce the Filing of an Application for REEQONUS(tm) (favipiravir) Tablets for the Treatment of COVID-19 under Health Canada's Interim Order Business Wire

Nov 24, 2020

07:18AM EST Health Canada Clears Appili Therapeutics For New Phase 3 Clinical Trial To Evaluate Avigan Tablets In Prevention Of COVID-19 In Exposed Individuals In The Community Benzinga

Oct 30, 2020

09:42AM EDT Appili Therapeutics Signs Collaboration, Development Supply Agreement With Dr. Reddy's Laboratories And Global Response Aid; Agreements To Accelerate Worldwide Development, Commercialization Of Avigan Tablets For Potential Treatment, Prevention Of COVID Benzinga

09:38AM EDT Appili Therapeutics Joins Dr. Reddy's, Global Response Aid, and FUJIFILM in Advancing Avigan(r) Tablets for the Potential Treatment of COVID-19 Business Wire

Aug 10, 2020

07:55AM EDT FDA Clears Appili Therapeutics to Expand its Phase 2 Clinical Trial of Favipiravir for the Potential Prevention of COVID-19 at U.S. Long-Term Care Facilities Benzinga

Share